IL6 and colitis: Consistent with the improvement in disease severity and colonic histopathological structure, in colitis models sGRP78 treatment significantly inhibited the production of pro-inflammatory mediators (TNF-α and IL-6) but increased the secretion of anti-inflammatory mediator IL-10 in plasma and in colonic tissues (Figures 3L-N).